HEPA (Hepion Pharmaceuticals, Inc.) Earnings per share for the last twelve months

Public company logo of Hepion Pharmaceuticals Inc. (HEPA)

Hepion Pharmaceuticals (HEPA) is accelerating the development of NASH therapy through partnerships with research centers, although development is patent-protected and requires massive capital to mitigate risks. The annual EPS TTM delta in the GURU.Markets chart shows that -5.80 represents the latest metric reading. The company's environmental strategy relies on laboratory safety and digital administration.

Hepion Pharmaceuticals, Inc. (HEPA): Earnings per share for the last twelve months from 02/11/2024 to 02/20/2024

Hepion Pharma - analytical breakdowns and key metrics (HEPA)

- market price and analyst price targets:
- business market valuation indicators:
Initial company analysis:Hepion Pharmaceuticals Inc.
Product sample of Hepion Pharmaceuticals Inc.

This indicator measures the dynamics of rolling net income, reflecting the rate of change in real earnings per share over a year. Investors utilize the current YoY ttm net income per share growth to determine market value momentum and assess overbought risks. A negative trend signals a degradation of fundamental metrics. For Hepion Pharmaceuticals (HEPA), this is confirmed by the collapse of clinical trials for its primary drug. The company is currently urgently cutting expenses to preserve its remaining capital.